Problem list:
| 1. |
HIV-infected child with prolonged fever
|
| 2. |
Corneal ulcers |
Laboratory investigations:
| |
CBC: Hb 6.1 g/dl, Hct 18%, WBC 3,600/mm3 (N=74%,
L=22%, M=16%) |
| |
CD4 T-cell count: 4% (20 cells/mm3) |
| |
Tuberculin skin test : Negative |
| |
Gastric washing for AFB (x 3 days): Negative |
| |
CXR: Cardiomegaly, generalized reticulo-nodular
infiltration both lungs suggesting miliary tuberculosis. (figure
3) |
| |
LP: WBC 13 celles/mm3 (lymphocyte 100%), protein
81mg%, sugar 35/129 mg%, gram stain and AFB: no organism seen |
| Echocardiogram: |
| |
Generalized cardiac dilatation, particularly left size was larger
than right side. Mild depressed LV systolic function. Small amount
of pericardial effusion. Most likely, the lesions are caused by
tuberculous myopathy. |
| Opthalmology consultation: |
| |
| |
Left eye
|
Right eye
|
| Visual Acuity |
Decreased (6/9) |
Decreased (6/9) |
| Conjunctiva |
Diffuse injected |
Diffuse injected |
| Pupil |
3 mm |
3 mm |
| Cornea |
Dendritic lesion (figure 4) |
Faint dendritic lesions |
 |
 |
|
Figure 3 CXR :Cardiomegaly, generalized
reticulo-nodular infiltration both lungs suggesting miliary
tuberculosis.
|
Figure 4 Dendritic lesion (courtesy
of Winai Chaidaroon M.D.)
|
|
| Diagnosis: HIV-infected child
(Category C3) with miliary tuberculosis, and herpes simplex keratitis
|
| |
| Treatment: |
|
1.
|
Miliary tuberculosis and meningitis : INH (15MKD),
RF (15MKD), PZA (25 MKD), S(25 MKD) |
|
2.
|
Herpes simplex keratitis: Acyclovir ointment 5 times/day |
|
3.
|
Cardiac dysfunction: Douzabox (1 tb tid), Enalapril
(0.125MKD), Digoxin (6.25 microgramKD) |
|
4.
|
Anemia: Ferrous Fumarate Co (1.5 tb OD) |
|
5.
|
Suspeced bacteremia on admission: Cefotaxime 100 MKD
IV x 7 days |
| |
|
| Course of illness: |
| |
| |
After she received the anti-tuberculous drugs
and cefotaxime for 4 days, the fever subsided as in figure
5. Her abdominal pain decreased. She gained appetite.
Her eye pain and photophobia slowly recovered. Her cardiac
condition gradually improved. The repeated chest radiography
1 month after antituberculous drugs and supportive treatment
was shown in figure 6. The heart
size was within normal limit. The previous mediastinal (hilar)
lymphadenopathy partially subsided. Although each nodule of
the "miliary" pattern was smaller in size, the pulmonary infiltration
persisted. |
| |
|
| |
Figure 5
|
| |
|
| |
Figure 6 The heart size was within normal
limit. The previous mediastinal (hilar) lymphadenopathy
partially subsided. The "miliary" pattern persisted, although
each nodule was smaller in size, .
|
|
DISCUSSION: |
|
>
|
She is an AIDS case (category C3). She had 2 opportunistic
infections, HSV keratitis and tuberculosis disease. |
|
>
|
The prolonged fever, pulmonary "miliary"
pattern, mediastinal (hilar) lymphadenopathy, cardiomegaly, pericardial
effusion, a visible left supraclevicular node, hepatomegaly, anemia
and slightly abnormal c.s.f. examination represent the clinical
manifestations of disseminated tuberculosis. Transmission of M.
tuberculosis was airborne, with inhalation of droplet nuclei produced
by her mother who had contagious, cavitary, pulmonary tuberculosis.
The initial pulmonary focus could be in the midlung zone which was
the common site. Small numbers of bacilli might be ingested by alveolar
macrophages. Infected macrophages were carried by lymphatics to
regional (hilar, mediastinal, and supraclavicular) lymph nodes,
and it spread hematogenously throughout the body as evidence by
small nodules "military" in the lungs, pericardial effusion, hepatomegaly
and abnormal c.s.f. findings. |
|
>
|
Although the fever subsided in the first
week of anti tuberculous drugs (plus cefotaxime), the pulmonary
manifestations (increased RR 36-44/min, creppitation) gradually
improved in 2-3 weeks. Cardiomegaly subsided and mediastinal (hilar)
lymphadenopathy partially subsided on the repeated CXR 1 month after
anti tuberculous drugs. It is not surprising that the "miliary"
pattern persisted on this repeated CXR. |
| QUESTIONS & ANSWERS: |
|
1. What is the hallmark of herpes simplex keratitis?(Ref
7-9)
|
| |
| |
Clinical symptoms: |
| |
> Pain
> Photophobia
> Blurred vision "
> Tearing "
> Redness |
|
| |
| |
Eye examination: |
| |
> corneal vesicles
> dendritic ulcers
> geographic ulcers
|
|
|
2. How to diagnose the disseminated tuberculosis?
(Ref 12)
|
| |
|
>
|
Clinical signs: general deterioration,
high fever, and dyspnea. Clinical signs that involve other
organs such as plural effusion, digestive problems, hepatosplenomegaly
and meningeal signs. |
|
>
|
Chest radiography: a "Miliary"
pattern on the chest radiography-extensive, tiny (1-2mm) nodules
resembling millet seeds, all the same size and spread symmetrically
over both lungs. |
|
>
|
Smear microscopy of sputum from
cases with disseminated (miliary) tuberculosis is usually
negative. |
|
| 3. What are the clinical characteristics suggesting
of disseminated tuberculosis or tuberculous meningitis? (Ref 12) |
| |
|
>
|
Clinical signs: nonspecific, progressive
deterioration of the states, mood, meningeal signs |
|
>
|
The tuberculin test is usually
negative |
|
>
|
Fundoscopic examination shows the
characteristic tuberculous lesions (choroidal tubercles)-round,
slightly raised yellow or whitish lesions of 1-3mm in diameter. |
|
>
|
Abnormal cerebrospinal fluid from
lumbar puncture |
|
| 4. What are the criteria of corticosteroid therapy
in tuberculosis? (Ref 13) |
| |
In patients with: |
| |
> tuberculous meningitis with increased intracranial
pressure |
| |
> acute pericardial effusion with tamponade |
| |
> pleural effusion with a shift of the mediastinum,
and acute respiratory failure |
| |
> miliary tuberculosis with alveolocapillary block
and cyanosis |
| |
> enlarged mediastinal lymphnodes that causing
respiratory difficulties or severe collapse consolidation lesion |
| |
(The dosage of corticosteroids should be in the anti-inflammatory
range-prednisolone, 1 to 2 mg/kg/day for 4-6 weeks with gradual
withdrawal) |
| 5. When to start HAART in patients with tuberculosis?
(Ref 14) |
| |
In patient with HIV-related tuberculosis, the priority
is to treat tuberculosis, especially smear-positive cases. However,
with careful management, patients with HIV-related tuberculosis
can have anti-retroviral therapy at the same times as tuberculosis
treatment. |
| |
| Possible options for anti-retroviral therapy
in the tuberculosis patients include: |
|
>
|
defer anti-retroviral therapy until
tuberculosis treatment is completed |
|
>
|
defer anti-retroviral therapy until
the end of the initial phase of tuberculosis treatment and
use ethambutal and isoniazid in the continuation phase |
|
>
|
treat tuberculosis with a rifampicin-containing
regimen and use of efavirenz + 2NRTIs; then change to a maximally
suppressive HAART regimen on completion of tuberculosis treatment. |
|
| 6. Anti-retroviral therapy and anti-tuberculosis
therapy: any drug interaction? (Ref 14) |
| |
Rifamipicin stimulates the activity of the
cytochrome P450 liver enzyme system that metabolizes PIs and NNRTIs.
This can lead to a reduction in the blood levels of PIs and NNRTIs.
PIs and NNRTIs can also enhance or inhibit this same enzyme system,
and lead to altered blood levels of rifampicin. |
| |
Isoniazid can produce peripheral neuropathy.
The NRTIs (didanosine, zalcitabine, and stavudine) may produce peripheral
neuropathy and there is a potential further toxicity if isoniazid
is added. Isoniazid also has an interaction with abacavir |
|
Follow up of the case : "Abdominal
discomfort" 5 weeks later
|
| References and suggested further reading: |
|
1.
|
American Thoracic Society, US Centers
for Disease Control and Prevention: Diagnostic Standards and Classification
of Tuberculosis in Adults and Children. This official statement
of the American Thoracic Society and the Centers for Disease Control
and Prevention was adopted by the ATS Board of Directors, July 1999.
This stat. Am J Respir Crit Care Med 2000 Apr; 161(4 Pt 1): 1376-95.
|
|
2.
|
Joint Tuberculosis Committee of the
British Thoracic Society: Chemotherapy and management of tuberculosis
in the United Kingdom: recommendations 1998. Thorax 1998 Jul; 53(7):
536-48. |
|
3.
|
Kim JH, Langston AA, Gallis HA: Miliary
tuberculosis: epidemiology, clinical manifestations, diagnosis,
and outcome. Rev Infect Dis 1990 Jul-Aug; 12(4): 583-90. |
|
4.
|
Klaus-Dieter, L., Cynthia L., Miliary
tuberculosis In: http://www.emedicine.com/med/topic1476.htm, Last
update February, 7 2003. Access: June, 30 2004 |
|
5.
|
Gaynor BD, Margolis TP, Cunningham ET:
Advances in diagnosis and management of herpetic uveitis. Int Ophthalmol
Clin 2000 Spring; 40(2): 85-109. |
|
6.
|
Herpetic Eye Disease Study Group: Oral
acyclovir for herpes simplex virus eye disease: effect on prevention
of epithelial keratitis and stromal keratitis. Arch Ophthalmol 2000
Aug; 118(8): 1030-6. |
|
7.
|
Herpetic Eye Disease Study Group: Acyclovir
for the prevention of recurrent herpes simplex virus eye disease.
N Engl J Med 1998 Jul 30; 339(5): 300-6. |
|
8.
|
Holland EJ, Schwartz GS: Classification
of herpes simplex virus keratitis. Cornea 1999 Mar; 18(2): 144-54. |
|
9.
|
Jim CW, David CR. Keratitis, Herpes Simplex
. In :
http://www.emedicine.com/oph/topic100.htm, Update: October 30, 2002,
Access: 30 June, 2004 |
|
10.
|
Julka RK; Deb M; Patwari AK Tuberculous
meningitis and miliary tuberculosis in children : a clinico-bacteriological
profile. Indian Journal of Tuberculosis. 1998 Jan; 45(1): 19-22
|
|
11.
|
F. van den Bos, M. Terken, L. Ypma J.
L. L. Kimpen, E. D. Nel, H. S. Schaaf, J. F. Schoemana and P. R.
Donald Tuberculous meningitis and miliary tuberculosis in young
children Tropical Medicine & International Health 2004; 9 (Issue
2): 309 |
|
12.
|
Ait-Khaled Nadia, Enarson Donald A.
Tuberculosis a Manual for Medical Students.World Health Organization
Geneva. 2003. |
|
13.
|
Starke Jeffrey R., Smith Kimberly C.
Tuberculosis. In: Feigin Ralph D., Cherry James D., Demmler Gail
J., Kaplan Sheldon L., editors. Textbook of Pediatric Infectious
Diseases. 5th ed. Philadelphia : Saunders; 2004. p.1337-79. |
|
14.
|
World Health Organization. Treatment of Tuberculosis:guidelines
for national programmes. 3rd ed. World Health Organization Geneva
2003.
|
|